Corline Biomedical AB

Corline adds to its base of scientific publications - Technique for anchoring growth factors to the Corline Heparin Surface published in Tissue Engineering

Pressmeddelande   •   Jan 14, 2010 15:43 CET

Early revascularization is necessary for long-term graft function in many areas of regenerative medicine, and is also crucial for pancreatic islet transplantation to patients with Diabetes Type-1. Previously published results show that the Corline Heparin Surface protects the islets from acute attack by the innate immune system of the blood following intraportal islet transplantation.  In the presently published study the ability of the CHS to bind to the angiogenic growth factor VEGF-A as a means of attracting endothelial cells to induce angiogenesis and revascularization was investigated. The capacity of VEGF-A to bind to immobilized heparin and how this affected the proliferation and adherence of endothelial cells was analyzed.


The results from the study are very promising.  Covering islets with Corline’s heparin surface combined with VEGF-A increased the adhesion of endothelial cells to the islet surface. Immobilized heparin on the islet surface may thus be a useful anchor molecule for achieving complete coverage of islets with angiogenic growth factors, ultimately improving islet revascularization and engraftment in pancreatic islet transplantation. The study also established that heparinized islets combined with VEGF-A demonstrated unaffected insulin release.


The published paper is written by scientists at Uppsala University (Cabric et al.) and has the title Anchoring of Vascular Endothelial Growth Factor to Surface-Immobilized Heparin on Pancreatic Islets: Implications for Stimulating Islet Angiogenesis and is published in Tissue Engineering: Part A, 2009 Dec 19 (Epub ahead of print).

About Corline and CHS


Corline is a biotechnology company based in Uppsala, Sweden, that develops, manufactures and distributes a proprietary patent protected heparin conjugate surface (CHS) that can be used both for medical devices and for Regenerative Medicine (cell therapy and tissue engineering). In 2008 the market for Regenerative Medicine totaled a 1.5 bn USD turnover, with a 90 % share being focused in the US. The US based market analysis company Life Science Intelligence, estimates the total potential to be over 100 bn USD.


CHS can be used to coat living cells and tissue without compromising their biological functions. CHS helps attenuate the local inflammation that is formed on and around grafts at transplantation, and promotes new blood vessels to grow more quickly to support the graft. For the patient, CHS potentially means better clinical outcome and a more rapid recovery from treatment.


Corline conducts pre-clinical and clinical studies within a number of cell and tissue therapy areas. These studies are a first step towards realizing the company’s vision of having its CHS platform technology widely used within the future Regenerative Medicine market. The CHS technology is protected by more than 20 granted and pending patents.


Corline is a privately held company, financially backed by members of the Crafoord family, primarily known for the development of Swedish medical device company Gambro (founded by Holger Crafoord), and Lars Sunnanväder, a well-known entrepreneur who has founded several medical device and biotechnology companies, e.g. heart/lung assist and coronary surgical device manufacturer Jostra, lung assist device manufacturer Novalung, Jotec, Jolife, Joline and other companies within this field.


For more information, please contact:


Henrik Nittmar, CEO

Tel. +46 (0)18 71 30 90